Cellectis is a clinical-stage biopharmaceutical company that is dedicated to developing the Next-Generation CAR T-Cells to Cure Cancer. With 23 years of expertise in gene editing, Cellectis utilizes its flagship TALEN® technology and pioneering electroporation system, PulseAgile, to harness the immune system and target cancer cells effectively. Their innovative immunotherapy product candidates are designed to have enhanced safety and efficacy attributes, enabling them to overcome mechanisms that inhibit immune system activity.

Cellectis is committed to good corporate governance, prioritizing the long-term interests of shareholders and building public trust. Their business practices foster an ethical, accountable, and transparent culture, reinforcing their innovative and collaborative nature. Partnerships play a crucial role for Cellectis, as they collaborate with like-minded organizations to develop allogeneic cancer therapies that address unmet medical needs worldwide.

Cellectis also demonstrates a strong commitment to corporate social responsibility, aiming to tackle the medical and food requirements of a growing global population. By leveraging their gene-editing technologies, they strive to advance the fields of immuno-oncology and plant sciences. For press enquiries or further information, their Media Team is readily available.

Cellectis prioritizes ethical standards, as evidenced by their Ethics Charter, which emphasizes employee work conditions and research objectives. They expect all associates, providers, and subcontractors to uphold these standards and demonstrate a commitment to human rights, labor rights, and the environment. Overall, Cellectis aims to revolutionize cancer treatment and make a positive impact on society through their cutting-edge innovations and responsible business practices